Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2013

View Archived Issues

Shionogi reveals development highlights of second quarter of fiscal 2013

Aclaris Therapeutics begins IND-directed program for A-101

Cells prepared for Nuvilex phase III pancreatic cancer trials

Armgo Pharma receives grant from Kennedy's Disease Association

Eisai offers overview of first half of fiscal 2013

OPKO Health initiates pivotal validation study for 4Kscore test for prostate cancer

Aposense PET radiotracer may identify high-risk atherosclerotic plaques

Novel B-raf inhibitor as a potential treatment for BRAF mutant cancers

[18F]LMI-1195 PET demonstrates potential for oncological indications

Substrate allows imaging of amino acid transporter ATB0+ overexpressing tumors

New model of familial dysautonomia allows testing of therapeutic strategies

Researchers in the U.S. patent novel neuroprotective oligopeptides

Gilead Sciences synthesizes new agents for HIV infection

Immunocore advances IMCgp-100 to phase IIa

Japanese group presents new FLT3 inhibitors for leukemia

Bayer Healthcare submits MAA in Europe for Eylea in DME

Researchers at Allergan prepare novel FPR2 modulators

HerpV vaccine meets primary endpoint in phase II study for genital herpes

French and U.S. team synthesize novel RyR1/RyR2 modulators

Health Canada approves Giotrif

CFI-400945 as a potent and selective first-in-class PLK-4 inhibitor for the treatment of cancer

NIBIO, Aeras and Create Vaccine sign basic agreement to develop TB vaccines

BioCryst begins dosing in phase IIa study of BCX-4161 for hereditary angioedema

Committee recommends discontinuation of phase II trial of TSO in Crohn's disease

Evotec and Johnson & Johnson Innovation establish collaboration in Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...